St. John's Wort for the Treatment of Psychiatric Disorders

Psychiatric Clinics of North America

Volumn 36, Issue 1, 2013, Pages 65-72

  Sarris, Jerome ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Antidepressant; Anxiety; Depression; Herbal medicine; Hypericum perforatum; Pharmacogenetics; Psychopharmacology; St. John's wort

Indexed keywords

CHINESE DRUG; CLOMIPRAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; PAROXETINE; PLACEBO; SERTRALINE; PLANT EXTRACT;

ANTIDEPRESSANT ACTIVITY; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSTHYMIA; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HERB DRUG INTERACTION; HUMAN; HYPERICUM PERFORATUM; LACTATION; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHARMACOGENETICS; PHOTOTHERAPY; POSTTRAUMATIC STRESS DISORDER; PREGNANCY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SEROTONIN SYNDROME; SINGLE DRUG DOSE; SKIN DISEASE; SOCIAL PHOBIA; SOMATIZATION; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); HYPERICUM; MENTAL DISORDERS; PHYTOTHERAPY;

CLINICAL TRIALS AS TOPIC; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; MENTAL DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84875620900     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2013.01.004     Document Type: Review

References (33)

1. Sarris J., Kavanagh D.J. Kava and St John's wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med 2009, 15(8):827-836.
2. Hypericum Depression Trial Study Group Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002, 287(14):1807-1814.
3. Shelton R.C., Keller M.B., Gelenberg A., et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001, 285(15):1978-1986.
4. Fournier J., DeRubeis R., Hollon S., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303(1):47-53.
5. Werneke U., Horn O., Taylor D. How effective is St John's wort? The evidence revisited. J Clin Psychiatry 2004, 65(5):611-617.
6. Linde K., Berner M., Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008, (4). CD000448.
7. Rahimi R., Nikfar S., Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(1):118-127.
8. Gastpar M., Singer A., Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005, 38(2):78-86.
9. Kasper S., Volz H.P., Moller H.J., et al. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression-a double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol 2008, 18(11):803-813.
10. Sarris J., Fava M., Schweitzer I., et al. St John's wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26 week RCT. Pharmacopsychiatry 2012, 45(7):275-278.
11. Wheatley D. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 1999, 15(1):33-37.
12. Martinez B., Kasper S., Ruhrmann S., et al. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 1994, 7(Suppl 1):S29-S33.
13. Findling R.L., McNamara N.K., O'Riordan M.A., et al. An open-label pilot study of St. John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry 2003, 42(8):908-914.
14. Simeon J., Nixon M.K., Milin R., et al. Open-label pilot study of St. John's wort in adolescent depression. J Child Adolesc Psychopharmacol 2005, 15(2):293-301.
15. Szegedi A., Kohnen R., Dienel A., et al. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005, 330(7490):503.
16. Taylor L.H., Kobak K.A. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000, 61(8):575-578.
17. Kobak K.A., Taylor L.V., Bystritsky A., et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005, 20(6):299-304.
18. Kobak K.A., Taylor L.V., Warner G., et al. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005, 25(1):51-58.
19. Volz H.P., Murck H., Kasper S., et al. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002, 164(3):294-300.
20. Muller T., Mannel M., Murck H., et al. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 2004, 66(4):538-547.
21. Weber W., Vander Stoep A., McCarty R.L., et al. Hypericum perforatum (St John's Wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA 2008, 299(22):2633-2641.
22. Butterweck V., Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 2007, 157(13-14):356-361.
23. Butterweck V. Mechanism of action of St John's wort in depression: what is known?. CNS Drugs 2003, 17(8):539-562.
24. Cott J. St John's wort 2010, Informacare. 2nd edition.
25. Jungke P., Ostrow G., Li J.L., et al. Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine. Psychopharmacology (Berl) 2010, 213(4):757-772.
26. Pennington K., Focking M., McManus C.A., et al. A proteomic investigation of similarities between conventional and herbal antidepressant treatments. J Psychopharmacol 2009, 23(5):520-530.
27. Wong M.L., O'Kirwan F., Hannestad J.P., et al. St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol Psychiatry 2004, 9(3):237-251.
28. Molendijk M.L., Bus B.A., Spinhoven P., et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16(11):1088-1095.
29. Sarris J. Current challenges in appraising complementary medicine evidence. Med J Aust 2012, 196(5):310-311.
30. Izzo A.A. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004, 42(3):139-148.
31. Whitten D., Myers D., Hawrelak J., et al. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006, 62(5):512-526.
32. Klier C.M., Schafer M.R., Schmid-Siegel B., et al. John's wort (Hypericum perforatum)-is it safe during breastfeeding?. Pharmacopsychiatry 2002, 35(1):29-30.
33. Moretti M.E., Maxson A., Hanna F., et al. Evaluating the safety of St. John's Wort in human pregnancy. Reprod Toxicol 2009, 28(1):96-99.